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Background: There is a lack of an instrument to evaluate systematic reviews of non-randomized studies in
epidemiological research. The Assessment of Multiple Systematic Reviews (AMSTAR) is widely used to evaluate
the scientific quality of systematic reviews, but it has not been validated for SRs of non-randomized studies. The
objective of this paper is to report our experience in applying AMSTAR to systematic reviews of non-randomized
studies in terms of applicability, reliability and feasibility. Thus, we applied AMSTAR to a recently published review
of 32 systematic reviews of non-randomized studies investigating the hospital volume-outcome relationship in surgery.
Results: The inter-rater reliability was high (0.76), albeit items 8 (scientific quality used in formulating conclusions),
9 (appropriate method to combine studies), and 11 (conflicts of interest) scored moderate (≤0.58). However, there
was a high heterogeneity between the two pairs of reviewers. In terms of feasibility, AMSTAR proved easy to
apply to systematic reviews of non-randomized studies, each review taking 5–10 minutes to complete. We faced
problems in applying three items, mainly related to scientific quality of the included studies.
Conclusions: AMSTAR showed good psychometric properties, comparable to prior findings in systematic reviews of
randomized controlled trials. AMSTAR can be applied to systematic reviews of non-randomized studies, although there
are some item specific issues users should be aware of. Revisions and extensions of AMSTAR might be helpful.
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Systematic reviews (SRs) are the cornerstone of evidence-
based health care. They can provide the highest level of
evidence [1,2]. Following this follows that conducting
methodological sound SRs is a crucial point for health care
professionals and researchers. Much focus has been put
on the critical appraisal of primary studies which is a
major part in an evidence synthesis. However, not only
the critical appraisal of primary studies is important,
but also the critical appraisal of SRs itself is important
in order to ensure a solid basis for decision making.
Over the years, many tools have been developed to as-
sess the methodological quality of SRs. The Overview
Quality Assessment Questionnaire (OQAQ) [3,4] and
Assessment of Multiple Systematic Reviews (AMSTAR)
[5-7] are two widely used tools for the assessment of sys-
tematic reviews. Two surveys of overviews (systematic* Correspondence: dawid.pieper@uni-wh.de
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unless otherwise stated.reviews of reviews) found both instruments to be used fre-
quently in this context [8,9].
It has to been acknowledged that AMSTAR has been
developed upon the OQAQ and the checklist by Sacks
[10] and can therefore be seen as the most recent tool,
being introduced in 2007. It consists of 11 items and
was found to be valid, reliable and easy to use [11]. Ac-
cording to the developers, AMSTAR can be applied to a
wide variety of SRs, although it is recognized that it has
only been tested on SRs of randomized controlled trials
evaluating treatment interventions [7].
However, it is well-known that RCTs are not feasible
for a wide range of research questions where we have to
rely on evidence from non-randomized studies (NRS) in-
stead. While investigating the hospital volume-outcome
relationship in surgery, we conducted an overview (re-
view of reviews) due to the huge amount of literature
published in this research area [12]. It is known that the
vast majority of studies investigating this relationship are
observational. Furthermore, volume is usually treated as
a continuous variable, while volume categories are oftenLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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Table 1 Inter-rater reliability
Items Kappa (95% CI)
1. Was an “a priori” design provided? 0.65 (0.54, 0.76)
2. Was there duplicate study selection and
data extraction?
0.94 (0.91, 0.96)
3. Was a comprehensive literature search
performed?
0.67 (0.62, 0.72)
4. Was the status of publication (i.e., grey
literature) used as an inclusion criterion?
0.85 (0.81, 0.88)
5. Was a list of studies (included and excluded)
provided?
0.75 (0.71, 0.79)
6. Were the characteristics of the included studies
provided?
0.91 (0.88, 0.94)
7. Was the scientific quality of the included studies
assessed and documented?
0.61 (0.56, 0.66)
8. Was the scientific quality of the included studies
used appropriately in formulating conclusions?
0.57 (0.51, 0.62)
9. Were the methods used to combine the findings
of studies appropriate?
0.53 (0.48, 0.57)
10. Was the likelihood of publication bias assessed? 1
11. Were potential conflicts of interest included? 0.58 (0.54, 0.63)
CI Confidence interval.
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we are mainly not investigating interventions, but risk
factors (defined as distinct volume categories). To the
best of our knowledge there was no assessment tool for
SRs of NRS available at the time of our work, so we de-
cided to apply AMSTAR to all included SRs, although
AMSTAR was originally not developed and tested for
this purpose.
The objective of this paper is to report our experience
and challenges in applying AMSTAR to SRs of risk fac-
tors in NRS in terms of applicability. Furthermore, we
also aimed to investigate the reliability and feasibility.
Methods
We used a recently published systematic review of sys-
tematic reviews investigating the volume-outcome rela-
tionship in surgery that was conducted by our research
team. Details of the methods have been reported else-
where [12]. In brief, we searched several databases for
systematic reviews investigating the relationship be-
tween high-volume hospitals and outcomes in surgery.
We included 32 SRs. Twenty six SRs focused on a
specific procedure while the remaining 6 SRs had no
specific focus and included several procedures. The
methodological quality of each SR was assessed inde-
pendently with the AMSTAR tool by two reviewers. In
total, there were three reviewers, one reviewer assessed
all SRs. The other two reviewers assessed each one half of
the SRs. SRs were randomized to the two reviewers. In
addition to the 11 items of AMSTAR, we added an add-
itional item dealing with multiple comparisons across pri-
mary studies. We were already aware of this problem from
prior publications on the same topic. However, this prob-
lem can be assumed to be topic-related and does not apply
to SRs of NRS in general. We decided to exclude this item
from the analysis against the background of this study.
In accordance with the AMSTAR developers, we de-
fine a NRS as a study with an observational design [13].
Reliability, feasibility and applicability
We followed the COSMIN initiative where reliability is
defined as “the degree to which the measurement is free
from measurement error” [14]. Feasibility is interested in
whether the measurement can be applied easily, given
constraints of time, money, and interpretability accord-
ing to the OMERACT initiative [15]. There is no well-
accepted definition of “applicability” in our context. We
have chosen the term “applicability” to give a direct to
answer to the question whether AMSTAR can be ap-
plied to SRs of NRS.
We calculated Cohen’s kappa as a measure of reliability
for each item (“yes” scores vs. any other scores) [16].
Kappa values of less than 0 were rated as less than chance
agreement; 0.01–0.20, slight agreement; 0.21–0.40, fairagreement; 0.41–0.60, moderate agreement; 0.61–0.80,
substantial agreement; and 0.81–0.99, almost perfect
agreement [17]. SPSS (version 21; SPSS Inc., Chicago, IL,
USA) was used to analyze the data, and the results were
expressed as means and 95% confidence intervals (CI) un-
less otherwise noted. Furthermore, we recorded the time
to complete scoring. We also listed any case where scoring
was difficult or impossible. Based on these findings we in-
vestigate the applicability of AMSTAR to SR of NRS by
reporting our experience on an item-by-item basis. In par-
ticularly, we highlight differences when applying AMSTAR
for SRs of RCTs compared with SRs of NRS.
Results
Reliability and feasibility
The inter-rater reliability was high, as indicated by an
overall kappa of 0.76 (95% CI: 0.76, 0.77) (range: 0.53 -
1.0). However, items 8 (scientific quality used in formu-
lating conclusions), 9 (appropriate method to combine
studies), and 11 (conflicts of interest) scored moderate at
0.57, 0.53, and 0.58, respectively (Table 1). Highest kappa
values scoring >0.90 were found for item 2 (double data
selection and data extraction), 6 (study characteristics),
and 10 (publication bias).
There was much difference between the two pairs of re-
viewers. The inter-rater reliability for pair 1 had an overall
kappa of 0.58 (95% CI: 0.57, 0.58), while the kappa for pair
2 had an overall kappa of 0.99 (95% CI: 0.98, 0.99).
AMSTAR proved to be easily applicable to SRs of
NRS, each review taking 5–10 minutes to complete with
no difference between the three reviewers.
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Item 1: was an “a priori” design provided?
In general, there should be no difference with respect to
this item. However, it might be more difficult to define
relevant study designs for inclusion, as the definition of
NRS allows for more than one study design (e.g. cohort
study, case–control study, controlled before-after study).
Item 2: was there duplicate study selection and data extraction?
There are no differences with respect to this item.
Item 3: was a comprehensive literature search performed?
There are no differences with respect to this item.
Item 4: was the status of publication (i.e., grey literature)
used as an inclusion criterion?
There are no differences with respect to this item.
Item 5: was a list of studies (included and excluded)
provided?
There are no differences with respect to this item.
Item 6: were the characteristics of the included studies
provided?
We faced some problems assessing this item. There were
some discussions between the reviewers about the suffi-
cient level of detail with respect to the nature of our in-
cluded SRs. For example, a high quality SR on the
volume-outcome relationship in pancreatic surgery pro-
vided characteristics on study period, cut-off values for
volume categories, number of patients, country of origin,
data source, data type (administrative vs. clinical), case
mix (adjustments for comorbidity, severity and acuity of
admission) and mortality rates and/or survival rates [18].
The authors provided no data on patient characteristics,
although they are explicitly mentioned in AMSTAR.
Item 7: was the scientific quality of the included studies
assessed and documented?
It turned out to be very tricky to answer this item as
there is no “gold standard” for the critical appraisal of
NRS. Thus, it is difficult to state any characteristics that
should be covered inevitably in assessing the methodo-
logical quality of NRS.
Item 8: was the scientific quality of the included studies
used appropriately in formulating conclusions?
This item is very much related to item 7. Assuming that
the quality of included studies has not been assessed ap-
propriately it is meaningless to assess whether the re-
sults of the critical appraisal were used appropriately in
formulating conclusions.Item 9: were the methods used to combine the findings of
studies appropriate?
We think that this item can be applied to SR of NRS.
Item 10: was the likelihood of publication bias assessed?
In general, this item can be easily applied to SRs of NRS.
Item 11: was the conflict of interest included?
This item can be applied to SR of NRS.
Discussion
AMSTAR showed good psychometric properties when
applied to SRs of NRS. The results of the inter-rater reli-
ability are comparable to prior findings when AMSTAR
had been applied to SRs of RCTs. There are only two re-
markable differences when comparing our findings to
one of the first validation studies where AMSTAR was
applied by two reviewers on 30 selected SRs [7]. We
yielded a much higher kappa value for item 4 (publica-
tion status): 0.85 vs. 0.38 and a much lower kappa value
for item 11 (conflicts of interest) 0.58 vs. 0.92. The low
kappa value for item 11 in our study can be explained by
differing understandings. Although the item is clearly
formulated and described, we had doubts about handling
it regarding the conflict of interests of health technology
agencies (HTA) as there were some HTA reports in our
sample of 32 reviews. Uncertainty arose in particular
whether governmental agencies had to state their con-
flicts of interests. As one might assume that they don’t
have any, it can be questioned whether it is necessary to
report this in a HTA. It took us less time to complete
the AMSTAR ratings for each review as in prior studies.
This is probably a result of applying AMSTAR by our re-
search team in many projects before. However, our re-
sults should be treated cautiously. We found a huge
difference for the inter-rater reliability among the two
pairs of reviewers, although all three reviewers had
much experience in applying AMSTAR and had worked
together on several occasions. There seems to be a de-
gree of interpretability in the items. We cannot preclude
that although we have randomized the SRs to the re-
viewers this has an impact on our results, as the sample
was small (n = 32). This remains difficult to interpret.
The aforementioned validation study included only 30
SRs and there were only two reviewers present [7].
Based on our experience in applying AMSTAR to SRs
of NRS, we think that AMSTAR can be applied to SRs
of NRS, although there are some specific points users
should take care of. We faced no problems in applying
the first five items of AMSTAR, but we faced problems
with respect to the remaining items. Items 6 to 9 re-
sulted in some discussions among the reviewers. They
mainly arose due to the lack of standards for NRS when
compared with RCTs. Items 10 and 11 can be applied to
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as well. However, we believe that these cannot be gen-
eralized to all SR of NRS, but depend on the topic of
the SR.
Looking at item 6 (study characteristics), it is not com-
pletely clear, whether the problems we faced with this
item were NRS specific. It might also be the case that
they simply reflect the difficulty of providing detailed in-
formation of a huge number of single studies in an art-
icle where space is limited.
Item 7 (critical appraisal) mainly refers to an adequate
quality assessment tool for NRS. There is no clearly rec-
ommended tool for assessing the quality of volume-
outcomes studies. One could also think of volume to be
a prognostic factor favoring a tool for prognostic studies
[19]. The Newcastle Ottawa Scale has been recom-
mended by a number of journals (e.g. the British Journal
of Surgery). At the time of writing it was validated for
the first time [20]. At the same time a research group
developed and validated a tool for assessing the risk of
bias in NRS. The Risk of Bias Assessment Tool for Non-
randomized Studies (RoBANS) showed moderate reli-
ability and promising validity [21]. According to the
authors, it was developed to be used for the assessment
of virtually all study designs except for RCTs. It is also
far from clear whether critical appraisal tools for NRS
can be applied to registry-based studies. For example,
questions dealing with incomplete data or missing data
can’t be applied easily as registries might only incorpor-
ate data of cases with complete data. Furthermore, data
quality of the registry is hardly to assess based on a jour-
nal article. Searching for secondary sources on the data
quality would be necessary in many cases as there is not
enough information in many registry-based studies.
In general, there is much heterogeneity in methods ap-
plied in observational studies [22]. To account for con-
founding and bias regression models are used often.
However, it has been debated that they are not able to
fully correct for all biases [23]. Understanding and asses-
sing the quality of regression models is much more diffi-
cult when opposed to most analysis methods used in
randomized controlled trials. One needs to have expert-
ise in epidemiology, statistics or related sciences to be
able to assess the methodological quality of NRS using
regression models due to their complexity and variation.
Discussions may also arise about the most appropriate
model for a study.
Item 9 (combining findings) was very challenging for
the raters. In our case, many SR also performed a meta-
analysis. It should be kept in mind that there are funda-
mental differences in assumptions made to meta-
analyses either for RCTs or NRS. It is assumed that a
RCT provides an unbiased estimate of the effect, while
observational studies yield estimates of association thatdo not necessarily reflect the true effect mainly due to
the effects of confounding and/or bias [24]. To over-
come this, it has been recommended to pool bias-
adjusted results for each study instead [25].
Most studies on the volume-outcome relationship
treat volume as a categorical variable. Taking volume as
an outcome measure can be confusing, as the number of
procedures performed can classify the same hospital as
low volume or high volume, depending on the geograph-
ical area. To overcome this, meta-analyses mostly pooled
the effect sizes of single studies when opposing the high-
est volume category to the lowest volume category. This
is also a problem with respect to item 10 (publication
bias). In our case, assessing this item was confusing. This
was mainly due to the fact of non-comparable effect
sizes as they originate from comparisons of various vol-
ume categories making them hardly comparable. A vis-
ual inspection of the funnel plot will be misleading
under these circumstances. This introduces the problem
that one might judge this item to be fulfilled if the au-
thors assess publication bias, although this should not
have been done for methodological reasons. It should be
kept in mind that publication bias is supposed to be
higher in observational studies than in RCTs [26]. Fur-
thermore, we suspect that there is a kind of “hidden”
publication bias because of registry data. If registry data
are available they must not be necessarily analyzed and
published. Registry data may also introduce the problem
of double-counting when persons who take part in a
study are also included in a registry leading to double-
analyses of one case.
Although item 11 (conflicts of interest) can be applied
to SRs of NRS it might be questioned here as well,
whether conflict of interest is not of much more import-
ance for randomized trials than for NRS. As RCTs are
considered to be the gold standard in assessing the effi-
cacy of pharmaceuticals, we assume that they are more
often industry-driven than in the case of studies on the
volume-outcome relationship in surgery.
When talking about NRS, we should notice that study
designs are often ill-defined. Classifying study designs
may lead to a surprisingly low agreement [27]. Even
questions such as “Was there a single cohort?” or “Was
there a comparison?” turned out to be difficult to an-
swer. Thus, a clearer concept of NRS should be pre-
sented to avoid confusions. For instance, the taxonomy
for studies of interventions and exposures presented by
Hartling et al. don’t use the term NRS [27]. Instead they
define non-randomized trials (NRTs) as “a study in
which individuals or groups of individuals (e.g. commu-
nity, classroom) are assigned to the intervention or con-
trol by a method that is not random (e.g. date of birth,
date of admission, judgement of the investigator). Indi-
viduals or groups are followed prospectively to assess
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lysis is the individual or the group, as appropriate.” Further-
more, beside of the known “classical” observational studies
such as cohort studies or case–control studies, there are a
number of additional study designs. The taxonomy pre-
sented by Hartling et al. differentiate between RCTs, NRTs,
prospective/retrospective cohort studies, interrupted time
series with/without comparison group, (controlled) before-
after-studies, (nested) case–control studies, non-concurrent
cohort studies, cross-sectional studies and non-comparative
studies. The Cochrane Handbook even distinguish more
study designs [28]. Our analyzed SRs included predomin-
antly cohort studies. Thus, our conclusions relate primarily
to SRs of cohort studies. We are not sure whether our find-
ings can be generalized to SRs of the above mentioned
study designs. Developers of tools for assessing the quality
of SRs of NRS should clearly describe their concept of
NRS. This may also include a distinction between review
types (e.g. intervention review or prognostic review). Keep-
ing the variety of study designs in mind (as described
above) the concept of NRS seems to be not more than a
differentiation from the concept of a RCT. Developing a
tool for SRs of NRS might be helpful when compared to
the current situation where we only have a validated tool
for SRs of RCTs, but it may neglect specific study design
characteristics. It should be questioned whether the con-
cept of NRS is too broad in this context.Conclusion
AMSTAR can be applied to SR of NRS, albeit we noticed
some problems. Nevertheless, it seems that all items can
be applied generally, although some revisions and exten-
sions might be helpful. This is more relevant to the ex-
planations of each item than for the formulation of
them. Future studies should also focus on the psycho-
metric properties of AMSTAR for SR of NRS. These
should also try to include more than one pair of raters.
Although we were able to show reliability for AMSTAR
for SR of NRS, we did not investigate validity. However,
there can’t be validity without reliability, while there can
be reliability without validity.
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